Skip to main content

Winter Clinical Miami, 2024

Filter
Close
Content type:
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
Han George, Gottlieb B. Alice, Armstrong April, et al.
Poster
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
J. F. Merola, C. Conrad, P. Foley, et al.
Poster
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Ingram R. John, Porter Martina, Chovatiya Raj, et al.
Poster
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Lebwohl Mark, Strober Bruce, Langley G. Richard, et al.
Poster
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Thaci Diamant, Armstrong April, Gordon B. Kenneth, et al.
Poster
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Merola F. Joseph, Conrad Curdin, Hampton Philip, et al.
Poster